BRIM Biotechnology, Inc.
Taiwan Stock ExchangeTotal Valuation
BRIM Biotechnology, Inc. carries a market capitalization of 2.72B, placing it among publicly traded companies globally. Its enterprise value stands at 2.23B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.72B |
| Enterprise Value | 2.23B |
Share Statistics
BRIM Biotechnology, Inc. currently has 133.02M shares outstanding.
| Shares Outstanding | 133.02M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 386.16, and the price-to-book ratio stands at 2.00.
| PE Ratio | N/A |
| PS Ratio | 386.16 |
| PB Ratio | 2.00 |
| P/TBV Ratio | 3.12 |
| P/FCF Ratio | -101.13 |
| P/OCF Ratio | -8.86 |
Enterprise Valuation
| EV / Sales | 271.04 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
BRIM Biotechnology, Inc. maintains a current ratio of 27.33, meaning it holds 27.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.79, indicating moderate leverage, while an interest coverage ratio of -828.34 demonstrates limited ability to service its debt obligations.
| Current Ratio | 27.33 |
| Quick Ratio | 25.97 |
| Debt / Equity | 0.79 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | -828.34 |
Financial Efficiency
| Return on Equity (ROE) | -24.08 |
| Return on Assets (ROA) | -21.19 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 25.37 |
Stock Price Statistics
BRIM Biotechnology, Inc.'s stock has declined approximately -33.71151% over the past 52 weeks. The 50-day moving average sits at 21.54, while the 200-day moving average is 25.22.
| Beta (5Y) | N/A |
| 52-Week Price Change | -33.71151% |
| 50-Day Moving Average | 21.54 |
| 200-Day Moving Average | 25.22 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, BRIM Biotechnology, Inc. generated 8.21M in revenue and converted that into -431.89M in net income, yielding earnings per share of -3.46. EBITDA reached -457.24M, while operating income came in at -457.24M.
| Revenue | 8.21M |
| Gross Profit | 920,000.00 |
| Operating Income | -457.24M |
| Pretax Income | -457.01M |
| Net Income | -431.89M |
| EBITDA | -457.24M |
| EBIT | -457.24M |
| Earnings Per Share (EPS) | -3.46 |
Balance Sheet
BRIM Biotechnology, Inc. holds 1.07B in cash and equivalents against 13.32M in total debt, resulting in a net debt position of -274.99M. Total book value stands at 1.59B, with working capital of 1.08B providing operational flexibility.
| Cash & Cash Equivalents | 1.07B |
| Total Debt | 13.32M |
| Net Debt | -274.99M |
| Equity (Book Value) | 1.59B |
| Book Value Per Share | 11.98 |
| Working Capital | 1.08B |
Cash Flow
BRIM Biotechnology, Inc. produced -358.11M in operating cash flow over the past twelve months. After subtracting -326.75M in capital expenditures, free cash flow totaled -684.86M - equivalent to -5.18 per share.
| Operating Cash Flow | -358.11M |
| Capital Expenditures | -326.75M |
| Free Cash Flow | -684.86M |
| FCF Per Share | -5.18 |
Margins
BRIM Biotechnology, Inc. operates with a gross margin of 11.20, reflecting its pricing power and cost economics. The operating margin of -5,567.30 and net profit margin of -5,258.58 provide insight into operational efficiency.
| Gross Margin | 11.20 |
| Operating Margin | -5,567.30 |
| Pretax Margin | -5,564.50 |
| Profit Margin | -5,258.58 |
| EBITDA Margin | -5,567.30 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.80 |
| FCF Yield | -0.99 |
Scores
BRIM Biotechnology, Inc. posts an Altman Z-Score of 39.17, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 39.17 |